Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci Acquires 49,261 Shares

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci purchased 49,261 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the acquisition, the chief executive officer now owns 1,097,458 shares of the company’s stock, valued at approximately $1,108,432.58. The trade was a 4.70 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Acurx Pharmaceuticals Trading Down 6.9 %

Acurx Pharmaceuticals stock opened at $0.75 on Thursday. The company has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.78. Acurx Pharmaceuticals, Inc. has a 12-month low of $0.68 and a 12-month high of $5.28. The stock has a market cap of $12.69 million, a P/E ratio of -0.69 and a beta of -1.71.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the company posted ($0.24) EPS. As a group, analysts forecast that Acurx Pharmaceuticals, Inc. will post -0.89 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Acurx Pharmaceuticals in a research note on Tuesday, December 10th.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC increased its holdings in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 295,075 shares of the company’s stock after purchasing an additional 16,975 shares during the quarter. Prospect Financial Services LLC owned 1.86% of Acurx Pharmaceuticals worth $561,000 at the end of the most recent reporting period. 11.53% of the stock is owned by hedge funds and other institutional investors.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.